Caribou Biosciences (NSDQ:CRBU) has announced the publication of data showing that its CRISPR hybrid RNA-DNA (chRDNA) guide technology supports better CRISPR associated protein 9 (Cas9) specificity compared with all-RNA guides. The Berkeley, California–based company’s technology thus enabled accuracy in intended genomic edits in cells while minimizing off-target events.
High Cas9 specificity is useful in the development of therapeutics.
In an article in Molecular Cell, report authors concluded that the findings “pave the way for utilizing customized chRDNAs in clinical applications.”
Steve Kanner
Caribou is developing allogeneic CAR-T cell therapies with multiple genome edits as potential therapies for hematologic malignancies. “By altering the position and number of DNA residues in our chRDNA guides, we readily achieve optimal on-target editing and minimize unintended off-target edits that m…